UTI treatment Market

• Growing prevalence and incidence of UTIs to propel market growth

The increased prevalence of UTIs is one of the major factors propelling growth in the market for treatments for urinary tract infections. UTI incidence is rising due to changing lifestyle patterns and interactions between UTIs and other medical diseases. It is anticipated that this will increase the demand for UTI treatment services. Compared to men, women are more likely to get the condition. UTIs are a possibility for about 50% of women worldwide at least once in their lifetime. This has a sizable population and needs a lot of attention.

In addition to gender, a number of additional factors contribute to the increased rate of UTIs, including obesity and diabetes. For instance, a 2020 study from the American College of Physicians and the Infectious Diseases Society of America found that UTIs account for about 6 million doctor visits annually in the US. Patients with pre-existing chronic diseases like coronary artery disease (CAD), chronic kidney disease (CKD), and diabetes mellitus (DM) had a higher risk of developing UTIs, according to a 2019 study published in the International Journal of Environmental Research and Public Health.

Furthermore, hospital-acquired UTI is one of the main examples among the MDR bacteria, which is a serious concern for the infectious disease sector. New kinds of germs, commonly known as superbugs, cause infections resistant to most therapeutic options. The mortality rate of these MDR bacteria ranges from 25% to 60%. Healthcare providers all throughout the world are really concerned about this. For instance, scientists at Queen's University Belfast in Ireland have been researching the causes of superbug resistance to first-line therapy. As a result, there are now more opportunities to comprehend infectious diseases and create new treatments for them.

Due to the widespread nature of this issue, significant funding is anticipated for the discovery of effective treatments. The government of Canada, the EU, and a few other wealthy nations have all made efforts to create novel treatments for microbes that are resistant to antibiotics.

However, catheters and other drainage devices are now being used by patients more frequently as a result of the increased prevalence of chronic kidney disorders, including bladder cancer and renal failure. Urinary catheter users are more likely to get complex UTIs.  According to the World Health Organization (WHO), urinary catheter patients run a 5% daily risk of developing bacteriuria, and 40% get nosocomial infections. Catheter-associated urinary tract infection is believed to be caused by a number of causes, including extended catheterization, failure to get systemic antibiotic therapy, bacterial colonization of drainage bags, rapid progression of underlying illnesses, and others.

Therefore, the market of UTI treatment will expand as urinary catheter use rises. Thus, it is anticipated that this aspect will accelerate UTI treatment market revenue globally.

The increasing prevalence of urinary tract infections (UTIs) globally is a primary driver of the Global UTI Treatment Market Industry. Data indicates that UTIs affect millions of individuals each year, particularly women, who are disproportionately impacted. The World Health Organization highlights that UTIs account for a significant portion of healthcare visits, leading to a growing demand for effective treatment options. As the global population ages and lifestyle factors contribute to higher UTI rates, the market is projected to reach 9.85 USD Billion in 2024. This trend underscores the necessity for innovative therapies and preventive measures in the Global UTI Treatment Market Industry.

By region, the study provides the market insights for UTI treatment into North America, Europe, Asia-Pacific and Rest of the World. North America UTI treatment market accounted for USD 4.2 billion in 2022 with a share of around 45.80% and is expected to exhibit a significant CAGR growth during the study period. This can be due to several factors, including the high disease burden, significant companies' existence, infrastructure availability, rising healthcare spending, rapid technological breakthroughs, proactive government measures, and increased patient awareness.

Further, the major countries studied in the market report for UTI treatment are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: UTI TREATMENT MARKET SHARE BY REGION 2022 (%)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Asia Pacific UTI treatment market accounts for the second-largest market share due to the high senior population and rising disease incidence rate. Growing population and the demand for affordable treatment are two variables that greatly impact market expansion. Moreover, China market of UTI treatment held the largest market share, and the India market of UTI treatment was the fastest growing market in the region.

Europe UTI treatment Market is expected to grow at the fastest CAGR from 2022 to 2030. The growth of the urinary tract infection (UTI) in the treatment market will be aided by the presence of many businesses that have made treatment simple. The construction of the health infrastructure is boosting growth overall. New product launches will also result from innovations. In Europe, there are more UTI instances. Further, the UK market of UTI treatment held the largest market share, and the Germany market of UTI treatment was the fastest growing market in the region.

Major market players are spending a lot of money on R&D to increase their product lines, which will help the market of UTI treatment grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the UTI treatment industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies adopted by manufacturers in the global UTI treatment industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, UTI treatment industry has provided medicine with some of the most significant benefits. The UTI treatment market major player such as Pfizer, Cipla Inc., GlaxoSmithKline PLC, Novartis AG, Shionogi & Co. Ltd, AstraZeneca and Bayer AG.

With its headquarters in Mumbai, Cipla Limited is a worldwide pharmaceutical corporation. Cipla focuses on creating medications to treat a variety of illnesses, including arthritis, diabetes, depression, cardiovascular disease, respiratory diseases, and many others. In October 2019, Elores was purchased by Cipla from Venus Remedies Ltd. Elores is a medication used to treat infections that can be fatal and is intended to combat antibiotic resistance. The most recent Phase-3 clinical investigation revealed that Elores is superior to meropenem for the treatment of severe urinary tract infections.

Pfizer Inc. is a worldwide pharmaceutical and biotechnology company with its main office in Manhattan, New York City, on 42nd Street. Two German businessmen founded the corporation in 1849 in New York. For the fields of immunology, cancer, cardiology, endocrinology, and neurology, Pfizer develops and produces pharmaceuticals and vaccines. Each of the company's top-selling medicines or goods brings in more than $1 billion in annual sales. In July 2019, Array BioPharma Inc. was fully acquired by Pfizer Inc. When Array BioPharma joined Pfizer, it added a fantastic portfolio, including the authorised combination usage. MEKTOVI and BRAFTOVI.